The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies
Official Title: A Phase II Study Evaluating the Safety and Efficacy of MGTA-145 in Combination With Plerixafor for the Mobilization and Transplantation of HLA-Matched Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Study ID: NCT04762875
Brief Summary: This research study tests a new medicine for mobilizing stem cells so they can be collected and used for allogeneic stem cell transplant for treatment of hematological malignancies. MGTA-145, the new medicine, will be given with plerixafor.
Detailed Description: This is a Phase II, open-label, multicenter, prospective study of MGTA-145 + plerixafor mobilized HLA-matched sibling and matched unrelated donor allografts for myeloablative hematopoietic stem cell transplantation (HSCT) in recipients with hematological malignancies. Donors will undergo 1 or 2 days of mobilization and apheresis.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
City of Hope National Medical Center, Duarte, California, United States
Stanford Health Care, Stanford, California, United States
Emory University Hospital, Atlanta, Georgia, United States
Mayo Clinic Rochester, Rochester, Minnesota, United States
Roswell Park Cancer Institute, Buffalo, New York, United States
Ohio State Medical Center, James Cancer Center, Columbus, Ohio, United States
M.D. Anderson Cancer Center, Houston, Texas, United States
Be The Match Collection Center Seattle, Seattle, Washington, United States
Name: Steven Devine, MD
Affiliation: National Marrow Donor Program
Role: STUDY_CHAIR